Hepatitis C associated cardiomyopathy: Potential pathogenic mechanisms and clinical implications

Medical Science Monitor

Volumn 14, Issue 5, 2008, Pages

  Sanchez, Mayra J ^a   Bergasa, Nora V ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WOODHULL MEDICAL CENTER   (United States)

Author keywords

Dilated cardiomyopathy; Extrahepatic manifestations of hepatitis C; Hepatitis C virus; Hepatitis C virus associated cardiomyopathy; Myocarditis; Tumor necrosis factor (TNF) alpha

Indexed keywords

ABARSARTAN; AMILODIPINE; ANTIVIRUS AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; FUROSEMIDE; LISINOPRIL; PEGINTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; APOPTOSIS; CELL DEATH; CIGARETTE SMOKING; CONGESTIVE CARDIOMYOPATHY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EXERCISE TEST; EXERCISE TOLERANCE; FOLLOW UP; GENETIC SUSCEPTIBILITY; HEART EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HEPATITIS C; HLA SYSTEM; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKINESIA; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; MITRAL VALVE REGURGITATION; MYOCARDIAL DISEASE; NEPHROTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; VIRUS LOAD;

ALLELES; ANTIVIRAL AGENTS; APOPTOSIS; CARDIOMYOPATHIES; COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C; HLA ANTIGENS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43549107924     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Cacoub P, Renou C, Rosenthal E et al: Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltimore), 2000; 79: 47-56
2. DeCastro M, Sanchez J, Herrera JF et al: Hepatitis C virus antibodies and liver disease in patients with porfiria cutanea tarda. Hepatology, 1993; 17: 551-57
3. Jubert C, Pawlotsky JM, Pouge F et al: Lichen planus and hepatitis C virus-related chronic active hepatitis. Arch Dermatol, 1994; 130: 73-76
4. Johnson RJ, Gretch DR, Couser WG et al: Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int, 1994; 46: 1700-4
5. Ramos-Casals M, Garcia-Carrasco M, Cervera R et al: Hepatitis C virus infection mimicking primary Sjögren's syndrome: a clinical and immunological description of 35 cases. Medicine (Baltimore), 2001; 80: 1-8
6. Matsumori A: Hepatitis C virus infection and cardiomyopathies. Cir Res, 2005; 96: 144-47
7. Teragaki M, Nishiguchi S, Takeuchi K et al: Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels, 2003; 18: 167-70
8. Matsumori A, Matoba Y, Sasayama S: Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation, 1995; 92: 2519-25
9. Bristow MR: Tumor Necrosis Factor-a and Cardiomyopathy. Circulation, 1998; 97: 1340-41
10. Billingham ME, Tazelaar HD: The morphological progression of viral myocarditis. Postgrad Med J, 1986; 62: 581-84
11. O'Connell JB: The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Inst J, 1987; 14: 268-75
12. Kawai C: From myocarditis to cardiomyopathy: mechanism of inflammation and cell death: learning from the past for the future. Circulation, 1999; 99: 1091-100
13. Neumann DA, Lane JR, Alen GS et al: Viral myocarditis leading to cardiomyopathy: do cytokines contribuye to pathogenesis? Clin Immunol Immunopathol, 1993; 68: 181-90
14. Gluck B, Schmidtke M, Merkle I et al: Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol, 2001; 33: 1615-26
15. Matsumori A, Yamada T, Suzuki H et al: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J, 1994; 72: 561-66
16. Satoh M, Tamura G, Segawa I et al: Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch, 1996; 427: 503-9
17. Kelleher DM, Telfor SR, Criscione L et al: Cytokines in murine lyme carditis: Th1 cytokine expression follows expression of proinflammatory cytokines in a susceptible mouse strain. J Infect Dis, 1998; 177: 242-46
18. Calabrese F, Carturan E, Chimenti C et al: Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol, 2004; 17: 1108-18
19. Torre-Aminone G, Kapadia S, Lee J et al: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation, 1996; 93: 704-11
20. Bryant D, Becker L, Richardson J et al: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 1998; 97: 1375-81
21. Torre-Aminone, G, Kapadia S, Lee J et al: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation, 1995; 92: 1487-93
22. Yokoyama T, Vaca L, Rossen R et al: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest, 1993; 92: 2303-12
23. Weir WG, Egan TM, Lopez-Lopez JR, Balke CW: Local control of excitation-contraction coupling in rat heart cells. J Physiol, 1994; 474: 463-71
24. 2+ transients. FEBS Lett, 1995; 376: 24-30
25. Duncan DJ, Hopkins PM, Harrisson SM: Negative inotropic effects of tumour necrosis factor-alpha and interleukin-1beta are ameliorated by alfentanil in rat ventricular myocytes. Br J. Pharmacology, 2007; 150: 720-26
26. Gwathmey JK, Copelas L, MacKinnon R et al: Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res, 1987; 61: 70-76
27. Hare JM, Keaney JF Jr, Balligand JL et al: Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest, 1995; 95: 360-66
28. Hare JM, Loh E, Creager MA, Colucci WS: Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation, 1995; 92: 2198-203
29. Schulz R, Nava E, Moncada S: Induction and potencial biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol, 1992; 105: 575-80
30. Ferdinandy P, Danial H, Ambrus I et al: Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Cir Res, 2000; 87: 241-47
31. Schulz R, Panas DL, Catena R et al: The role of nitric oxide in cardiac depression induced by interleukin-1beta and tumour necrosis factor-alpha. Br J Pharmacol, 1995; 114: 27-34
32. Evans HG, Lewis MJ, Shah AM: Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res, 1993, 27: 1486-90
33. Balligand JL, Ungureanu-Longrois D, Simmons WW: Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem, 1994; 269: 27580-88
34. Panas D, Khadour FH, Szabo C, Schulz R: Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol, 1998; 275(3 Pt 2): H1016-23
35. Csont T, Viappiani S, Sawicka J et al: The involvementof superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. J Mol Cell Cardiol, 2005; 39: 833-40. Epub 2005 Sep 19
36. Hong X, Yu RB, Sun NX et al: Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol, 2005; 11: 7302-7
37. Naruse TK, Inoko H: HLA and hepatitis C virus positive cardiomyopathy. Nippon Rinsho, 2000; 58: 212-17
38. Shichi D, Kikkawa EF, Ota M et al: The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens, 2005; 66: 200-8
39. Altomonte M, Pucillo C, Maio M: The overlooked "Nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. J Cellu Physiology, 1999; 179: 251-56
40. Charron D: HLA class II disease associations: molecular basis. J Autoimmun, 1992, 5(Suppl.A): 45-53
41. Okabe M, Fukuda K, Arakawa K, Kikuchi M: Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation, 1997; 96: 22-24
42. Pape GR, Gerlach TJ, Diepolder HM et al: Role of the specific T-cell response for clearance and control of hepatitis c virus. J Viral Hepat, 1999; 6(Suppl.1): 36-43
43. Gerlach JT, Diepolder HM, Jung MC: Recurrence of hepatitis C virus after loss of virus-specific CD4 (+) T-cell response in acute hepatitis C. Gastroenterology, 1999; 117(4): 933-41
44. O'Garra N, Robinson D: Development and function of T helper 1 cells. Adv Immunol, 2004; 83: 133-62
45. Decker JM. Cytokines. http://microvet.arizona.edu/Courses/MIC419/ Tutorials/cytokines.html, publication date: February 19, 2006, accessed on August 19, 2006
46. Mourad W, Al-Daccak R, Chatila T, Geha RS: Staphylococcal superantigens as inducers of signal transduction in MHC class II-positive cells. Semin Immunol, 1993; 5: 47-55
47. Mourad W, Mehindate K, Schall TJ, McColl SR: Engagement of major histocompatibility complex class II molecules by superantigenes induces inflammatory cytokines gene expression in human rheumatoid fibroblast-like synoviocytes. J Exp Med, 1992; 175: 613-16
48. Li H, Llera A, Malchiodi EL, Mariuzza RA: The structural basis of T cell activation by superantigens. Annu Rev Immunol, 1999; 17: 435-66
49. Al-Daccak R, Mehindate K, Hebert J et al: Mycoplasma arthritidis -derived superantigen induces proinflammatory monokine gene expression in the THP-1 human monocytic cell line. Infect Immun, 1994; 62: 2409-16
50. Mehindate K, Al-Daccak R, Schall TJ , Mourad W: Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. J Biol Chem, 1994; 269: 32063-69
51. Alvarez-Ossorio L, Johannsen M, Alvarez-Ossorio R et al: Cytokine induction by Micoplasma arthritidis-derived superantigen (MAS), but not TSST-1 or SEC-3, is correlated to certain HLA-DR types. Scand J Immunol, 1998, 47: 43-47
52. Alvarez-Ossorio L, Johannsen M, Russlies M et al: HLA-dependent heterogeneous T cell response to Mycoplasma arthritis-derived superantigen (MAS), Med Microbiol Immunol (Berl), 1997; 185: 245-51
53. Rink L, Nicklas W, Luhm J et al: Induction of proinflammatory cytokine network by Mycoplasma arthritidis-derived superantigen (MAS). J Interferon Cytokine Res, 1996; 16: 861-68
54. Altomonte M, Pucillo C, Damante G, Maio M: Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. J Immunol, 1993; 151: 5115-22
55. Price P, Witt C, Allcock RJN et al: The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunogenetics, 1999; 167: 257-74
56. Cheong KY, Allcock RJN, Eerligh P et al: Localization of central MHC genes influencing type 1 diabetes. Hum Immunol, 2001; 62: 1363-70
57. Ota M, Katsuyama Y, Kimura A et al: A second susceptibility gene for developing rheumatoid arthritis in the human MHC is localized within a 70-kb interval telomeric of the TNF genes in the HLA class III region. Genomics, 2001; 71: 263-70
58. Gruen JR, Weissman SM: Evolving views of the major histocompatibility complex. Blood, 1997; 90(11): 4252-65
59. Hayden MS, Ghosh S: Signaling to NF-κB. Genes and Develop, 2004; 18: 2195-24
60. Mathys JM, Melanson SM, Schiffer-Alberts DJ et al: NF-κB modulates TNF-α production by alveolar macrophages in asymptomatic HIV-seropositive individuals. J Immunology, 2000; 164: 1588-94
61. Semple JI, Brown SE, Sanderson CM, Campbell RD: A distinct bipartite motif is required for the localization of inhibitory κB-like (IκBL) protein to nuclear speckles. Biochem J, 2002; 361: 489-96
62. Okamoto K, Makino S, Yoshikawa Y et al: Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am J Hum Genet, 2003; 72: 302-12
63. de la Concha EG, Fernandes-Arquero M, Lopez-Nava G et al: Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology, 2000; 119: 1491-95
64. Miterski B, Bohringer S, Klein W et al: Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun, 2002; 3(4): 211-19
65. Allcock RJN, Williams JH, Price P: The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production. Genes to Cells, 2001; 6: 487-94
66. Wong A, Allcock RJ, Karey YM: Alleles of the proximal promoter of BAT1, a putative anti-inflammatory gene adjacent to the TNF cluster, reduce transcription on a disease-associated MHC haplotype. Genes to Cells, 2003; 8: 403-12
67. Sugimoto K, Stadanlick J, Ikeda F et al: Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology, 2003; 37(3): 590-99
68. Pape GR, Gerlach TJ, Diepolder HM et al: Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat, 1999; 6(Suppl.1): 36-40
69. Gerlach JT, Diepolder HM, Jung MC: Recurrence of hepatitis C virus after loss of virus-specific CD4 (+) T-cell response in acute hepatitis C. Gastroenterology, 1999; 117(4): 933-41
70. Matsumori A, Sasayama S: Never Aspects of Pathogenesis of Heart Failure: Hepatitis C virus infection in Myocarditis and Cardiomyopathy. J Card Fail, 1996; 2(4 Suppl.): S187-94
71. Frustaci A, Calabrese F, Chimenti C et al: Lone Hepatitis C virus Myocarditis responsive to immunosuppressive therapy. Chest, 2002; 122: 1348-56
72. Omura T, Yoshiyama M, Hayashi T et al: Core protein of hepatitis c virus induced cardiomyopathy. Circ Res, 2005; 96(2): 148-50
73. Nongliao Z, Khoshnan A, Schneider R et al: Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol, 1998; 72(5): 3691-97
74. Korenaga M, Okuda M, Otani K et al: Mitochondrial dysfunction in hepatitis C, J Clin Gastroenterol, 2005; 39 (4 Suppl.2): S162-66
75. Okuda M, Li K, Beard MR, Showalter LA et al: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology, 2002; 122(2): 366-75
76. Korenaga M, Wang T, Li Y et al: Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem, 2005, 280(45): 37481-88
77. Taylor ER, Hurrell F, Shannon RJ et al: Reversible Glutathionylation of Complex I Increases Mitochondrial Superoxide Formation. J Biol Chem, 2003; 278(22): 19603-10
78. Meldrum DR, Dinarello CA, Cleveland JC Jr et al: Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery, 1998; 124(2): 291-96
79. Ungvari Z, Gupte SA, Recchia FA et al: Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol, 2005; 3(3): 221-29
80. Sam F, Kerstetter DL, Pimental DR et al: Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail, 2005 ;11(6): 473-80
81. von Harsdorf R, Li PF, Dietz R: Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation, 1999; 99(22): 2934-41
82. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev, 2001; 15(22): 2922-33
83. Baker SJ, Reddy EP: Modulation of life and death by the TNF receptor superfamily. Oncogene, 1998; 17: 3261-70
84. Adhihetty PJ, Hood DA: Mechanisms of Apoptosis in Skeletal Muscles. Basic Appl Myol, 2003; 13(4): 171-79
85. McMurray JJ, Pfeffer MA: Heart failure. Lancet, 2005; 365: 1877-89
86. Armstrong GL: Modelling the epidemiology of hepatitis C and its complications. International J of Epidemiology, 2003; 32: 725-26